In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Mereo Biopharma Group Plc ADR’s stock clocked out at $2.61, up 4.40% from its previous closing price of $2.50. In other words, the price has increased by $4.40 from its previous closing price. On the day, 1.65 million shares were traded. MREO stock price reached its highest trading level at $2.64 during the session, while it also had its lowest trading level at $2.5.
Ratios:
To gain a deeper understanding of MREO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.40 and its Current Ratio is at 5.40. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on March 27, 2025, initiated with a Overweight rating and assigned the stock a target price of $7.
On December 06, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $7.
On June 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $8.Robert W. Baird initiated its Outperform rating on June 13, 2024, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when Scots-Knight Denise sold 60,046 shares for $4.22 per share. The transaction valued at 253,454 led to the insider holds 808,921 shares of the business.
Scots-Knight Denise sold 28,611 shares of MREO for $127,968 on Sep 12 ’24. The Chief Executive Officer now owns 868,967 shares after completing the transaction at $4.47 per share. On Sep 13 ’24, another insider, Lewicki John A., who serves as the Chief Scientific Officer of the company, sold 10,937 shares for $4.22 each. As a result, the insider received 46,165 and left with 78,630 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 414989984 and an Enterprise Value of 2011580800.
Stock Price History:
The Beta on a monthly basis for MREO is 0.47, which has changed by -0.14426231 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, MREO has reached a high of $5.02, while it has fallen to a 52-week low of $1.58. The 50-Day Moving Average of the stock is 8.67%, while the 200-Day Moving Average is calculated to be -25.61%.
Shares Statistics:
It appears that MREO traded 1.45M shares on average per day over the past three months and 2175340 shares per day over the past ten days. A total of 155.15M shares are outstanding, with a floating share count of 139.69M. Insiders hold about 9.96% of the company’s shares, while institutions hold 66.28% stake in the company. Shares short for MREO as of 1744675200 were 6597120 with a Short Ratio of 4.53, compared to 1741910400 on 6026904. Therefore, it implies a Short% of Shares Outstanding of 6597120 and a Short% of Float of 5.84.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 6 analysts are dedicated to thoroughly evaluating and rating the performance of Mereo Biopharma Group Plc ADR (MREO) in the stock market.The consensus estimate for the next quarter is $-0.01, with high estimates of $0.04 and low estimates of $-0.08.
Analysts are recommending an EPS of between $0.06 and $-0.07 for the fiscal current year, implying an average EPS of $-0.04. EPS for the following year is $-0.02, with 6.0 analysts recommending between $0.06 and $-0.07.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $37.26M in the next fiscal year. The high estimate is $72.36M and the low estimate is $1.01M.
